Literature DB >> 1586723

Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers?

M M Horowitz1, D Przepiorka, R E Champlin, R P Gale, A Gratwohl, R H Herzig, H G Prentice, A A Rimm, O Ringdén, M M Bortin.   

Abstract

There is substantial evidence that the volume of medical procedures in a hospital has an inverse relationship with mortality. We analyzed data for 1313 recipients of HLA-identical sibling bone marrow transplants for early leukemia (acute leukemia in first remission or chronic myelogenous leukemia in first chronic phase) to determine whether transplant outcome differed in small and large centers. Transplants were performed in 86 bone marrow transplant centers active between the years 1983 and 1988, which participated in the International Bone Marrow Transplant Registry. Twenty-one (24%) centers performed five or fewer allogeneic transplants per year during the study period; five (6%) performed more than 40 per year. After adjustment for differences in patient and disease characteristics, the relative risks of treatment-related mortality (1.53, P less than .01) and treatment failure (1.38, P less than .04) were higher among patients who received transplants at centers doing five or fewer transplants per year than among those at larger centers. Among patients receiving transplants in centers performing more than five transplants a year, there was no statistically significant correlation between number of transplants and outcome.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1586723

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Authors:  Tait D Shanafelt; Neil E Kay; Kari G Rabe; David J Inwards; Clive S Zent; Jose F Leis; Susan M Schwager; Carrie A Thompson; Deborah A Bowen; Thomas E Witzig; Susan L Slager; Timothy G Call
Journal:  Cancer       Date:  2011-08-26       Impact factor: 6.860

2.  Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT.

Authors:  Sebastian Giebel; Myriam Labopin; Adalberto Ibatici; Paul Browne; Tomasz Czerw; Gerard Socie; Ali Unal; Slawomira Kyrcz-Krzemien; Andrea Bacigalupo; Hakan Goker; Mike Potter; Caroline L Furness; Grant McQuaker; Dietrich Beelen; Noel Milpied; Antonio Campos; Charles Craddock; Arnon Nagler; Mohamad Mohty
Journal:  Oncologist       Date:  2016-02-11

3.  The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).

Authors:  Bruno C Medeiros; Megan Othus; Martin S Tallman; Zhuoxin Sun; Hugo F Fernandez; Jacob M Rowe; Hillard M Lazarus; Frederick R Appelbaum; Selina M Luger; Mark R Litzow; Harry P Erba
Journal:  Leuk Res       Date:  2019-01-17       Impact factor: 3.156

4.  Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.

Authors:  Anita D'Souza; Angela Dispenzieri; Baldeep Wirk; Mei-Jie Zhang; Jiaxing Huang; Morie A Gertz; Robert A Kyle; Shaji Kumar; Raymond L Comenzo; Robert Peter Gale; Hillard M Lazarus; Bipin N Savani; Robert F Cornell; Brendan M Weiss; Dan T Vogl; César O Freytes; Emma C Scott; Heather J Landau; Jan S Moreb; Luciano J Costa; Muthalagu Ramanathan; Natalie S Callander; Rammurti T Kamble; Richard F Olsson; Siddhartha Ganguly; Taiga Nishihori; Tamila L Kindwall-Keller; William A Wood; Tomer M Mark; Parameswaran Hari
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

Review 5.  Is cancer care best at high-volume providers?

Authors:  B E Hillner
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

6.  The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation.

Authors:  Karim E Abou-Nassar; Haesook T Kim; Jeff Blossom; Vincent T Ho; Robert J Soiffer; Corey S Cutler; Edwin P Alyea; John Koreth; Joseph H Antin; Philippe Armand
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-08       Impact factor: 5.742

7.  Factors associated with transfusion requirements during treatment for acute myelogenous leukemia.

Authors:  G Favre; M Fopp; J Gmür; A Tichelli; M F Fey; A Tobler; E Schatzmann; A Gratwohl
Journal:  Ann Hematol       Date:  1993-10       Impact factor: 3.673

8.  Bone marrow transplantation today.

Authors:  A Gratwohl
Journal:  Support Care Cancer       Date:  1994-01       Impact factor: 3.603

9.  Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups.

Authors:  Dianne Pulte; Maria Theresa Redaniel; Lina Jansen; Hermann Brenner; Mona Jeffreys
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

10.  Rates of complete diagnostic testing for patients with acute myeloid leukemia.

Authors:  Tara L Lin; Travis Williams; Jianghua He; Omar S Aljitawi; Siddhartha Ganguly; Sunil Abhyankar; Allan Fleming; Heather Male; Joseph P McGuirk
Journal:  Cancer Med       Date:  2015-01-26       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.